The Journal of Organic Chemistry
Article
6-Amino-5-cyano-4-phenyl-1-o-tolyl-2(1H)-pyrimidinone (5a).
Yield: 82% (248 mg). White solid, mp 227−229 °C. IR (KBr,
cm−1): 3514, 3462, 2217, 1666, 1599, 1581, 1555. 1H NMR: (DMSO-
d6, 300 MHz): δ 2.08 (s, 3H, CH3), 7.30−7.45 (m, 6H), 7.52−7.62
(m, 3H), 7.85 (dd, J = 9 Hz, J = 3 Hz, 2H), the NH2 are located under
the aromatic area according to the total integration. 13C NMR
(DMSO-d6, 75 MHz): δ 17.1 (CH3), 72.7 (C-CN), 117.0 (CN); 9C-
Harom:128.4, 128.7, 128.76 (×2), 128.83 (×2), 130.2, 131.5, 132.0;
5Cq: 133.8, 136.1, 137.3, 153.4, 160.1; 172.2 (CO). MS-(+)ESI, m/z
(%): 303 ([M + H]+, 100), 325 ([M + Na]+, 4), 627 ([2 M + Na]+,
38). HRMS-ESI (m/z): cald for C18H15N4O [M + H]+ 303.1246,
found 303.1257.
(br, 1H, NH). 13C NMR (DMSO-d6, 75 MHz): δ 21.5, 55.3, 123.1,
124.4, 125.7, 126.0, 126.6, 127.6, 128.1, 128.5, 128.8, 129.5, 129.8,
134.2, 135.2, 142.1, 157.0, 191.7.
General Procedure for Preparation of 2(1H)-pyrimidine-
thiones (6a and 6b). To a solution of Na (0.14 g, 6 mmol) in dry
MeOH (15 mL) were added malononitrile (0.33 g, 5 mmol) and the
imidate 8 (5 mmol). The solution was stirred under reflux for 4 h and
cooled to room temperature. Glacial HOAc (0.4 g, 7 mmol) and water
(50 mL) were added. The precipitate was collected by filtration and
recrystallized from MeOH to yield the 2(1H)-pyrimidinethione 6.
6-Amino-5-cyano-1-o-tolyl-4-p-tolyl-2(1H)-pyrimidinethione
(6a). Yield: 63% (1.04 g). Yellow solid, mp 251−253 °C. IR (KBr,
cm−1): 3533, 3429, 2214, 1699, 1610, 1545, 1516, 1318, 1243, 1172,
6-Amino-5-cyano-1-o-tolyl-4-p-tolyl-2(1H)-pyrimidinone (5b).
1
1149, 1007. H NMR (CD3OD, 600 MHz): δ 2.19 (s, 3H, o-CH3),
Yield: 96% (303 mg). White solid, mp 221−223 °C. IR (KBr,
1
cm−1): 3510, 3462, 2210, 1671, 1645, 1609, 1578, 1548. H NMR
2.44 (s, 3H, p-CH3), 7.24 (d, J = 7.2 Hz, 1H), 7.36 (dd, J = 0.6 Hz, J =
8.4 Hz, 2H), 7.43−7.50 (m, 3H), 7.88 (d, J = 8.4 Hz, 2H). (DMSO-d6,
400 MHz): δ 2.08 (s, 3H, o-CH3), 2.41 (s, 3H, p-CH3), 7.26 (dd, J =
6.4 Hz, J = 2 Hz, 1H), 7.37−7.42 (m, 5H), 7.82 (d, J = 8 Hz, 2H). 13C
NMR (DMSO-d6, 125 MHz): δ 16.7 (o-CH3), 21.0 (p-CH3), 77.5 (C-
CN), 116.0 (CN); 8C-Harom: 127.84, 128.27, 128.68 (×2), 128.91
(×2), 129.77, 131.84; 6Cq: 132.98, 134.97, 136.5, 141.56, 157.78,
164.03; 180.73 (CS). MS-(+)ESI, m/z (%): 333 ([M + H]+, 100),
355 ([M + Na]+, 12). HRMS-ESI (m/z): cald for C19H17N4S [M +
H]+ 333.1174, found 333.1181.
(DMSO-d6, 300 MHz): δ 2.07 (s, 3H, o-CH3), 2.40 (s, 3H, p-CH3),
7.29−7.44 (m, 6H), 7.77 (d, J = 9 Hz, 2H), the NH2 are located under
the aromatic area according to the total integration. 13C NMR
(DMSO-d6, 75 MHz): δ 17.2 (o-CH3), 21.5 (p-CH3), 72.4 (C-CN),
117.1 (CN); 8C-Harom:128.3, 128.8, 128.9 (×2), 129.3 (×2), 130.2,
132.0; 6Cq: 133.9, 134.5, 136.1, 141.6, 153.4, 160.1; 171.9 (CO).
MS-(+)ESI, m/z (%): 317 ([M + H]+, 100), 339 ([M + Na]+, 3), 655
([2 M + Na]+, 38). HRMS-ESI (m/z): cald for C19H17N4O [M + H]+
317.1402, found 317.1416.
6-Amino-5-cyano-1-(naphthalen-1-yl)-4-p-tolyl-2(1H)-pyrimidi-
nethione (6b). Yield: 65% (1.2 g). Yellow solid, mp 263−265 °C. IR
(KBr, cm−1): 3527, 3386, 2215, 1698, 1610, 1551, 1518, 1445, 1330,
1242, 1173, 1007. 1H NMR: (DMSO-d6, 300 MHz): δ 2.44 (s, 3H, p-
CH3), 7.41 (d, J = 9 Hz, 2H), 7.54−7.69 (m, 6H), 7.88 (d, J = 9 Hz,
2H), 8.08−8.10 (m, 2H). (CD3OD, 600 MHz): δ 2.47 (s, 3H, p-CH3),
7.39 (d, J = 8.1 Hz, 2H), 7.56−7.62 (m, 4H), 7.68 (t, J = 7.8 Hz, 1H),
7.93 (d, J = 8.1 Hz, 2H), 8.05 (d, J = 7.8 Hz, 1H), 8.12 (d, J = 7.8 Hz,
1H). 13C NMR (DMSO-d6, 75 MHz): δ 21.6 (p-CH3), 77.7 (C-CN),
116.2 (CN); 11C-Harom:121.5, 126.3, 126.6, 127.17(×2?), 128.55,
128.66 (×2), 128.84 (×2), 129.93; 7Cq: 128.24, 133.2, 134.0, 134.7,
141.4, 158.48, 164.24; 182.3 (CS). MS-(+)ESI, m/z (%): 369 ([M +
H]+, 100), 391 ([M + Na]+, 10). HRMS-ESI (m/z): cald for
C22H17N4S [M + H]+ 369.1174, found 369.1165.
Chromatographic Screening. The resolution of the enantiomers
of compounds 5a−5f and 6a and 6b was performed on several chiral
stationary phases using various eluents to select the best conditions for
future semipreparative separation. Immobilized Daicel columns
Chiralpak IA, IB, IC, and ID were used in all cases, and (S,S)-Ulmo
was also screened in some cases. The temperature was regulated at 25
°C, and the flow rate was set at 1 mL/min. For each compound,
excellent separations with α > 1.65 were achieved on one or several
columns. For all the samples, Chiralpak IB gave very poor or no
separation, whereas IA, IC, or ID columns produced baseline
separation. For solubility reasons, the racemates were dissolved in a
mixture of ethanol and chloroform, which prevented the use of coated
polysaccharide phases. The separations were monitored using a DAD
detector and a circular dichroism detector set at 254 nm. All the
chromatographic data including mobile phase composition, retention
times and retention factors, enantioseparation and resolution obtained
from screening experiments are reported for each compound in the
Supporting Information. When the sensitivity was sufficient, the CD
signs at 254 nm in the mobile phase of the first and second eluted
enantiomers are also given.
6-Amino-4-benzyl-5-cyano-1-o-tolyl-2(1H)-pyrimidinone (5c).
Yield: 92% (290 mg). White solid, mp 256−258 °C. IR (KBr,
cm−1): 3517, 3464, 2212, 1682, 1611, 1567, 1529. 1H NMR (DMSO-
d6, 300 MHz): 1H NMR (DMSO-d6, 300 MHz): δ 2.00 (s, 3H, CH3),
3.89 (d, J = 15 Hz, 1H, CH2), 3.95 (d, J = 15 Hz, 1H, CH2), 7.22−7.41
(m, 9H), 7.80 (br, 2H−NH2). 13C NMR (DMSO-d6, 75 MHz): δ
17.1(o-CH3), 43.4 (CH2), 73.6 (C-CN), 116.4 (CN); 9C-Harom: 127.3,
128.3, 128.8, 129.0 (×2), 129.5 (×2), 130.2, 131.9; 5Cq: 133.8, 136.0,
137.0, 153.5, 159.3; 175.7 (CO). MS-(+)ESI, m/z (%): 317 ([M +
H]+, 100), 339 ([M + Na]+, 4), 655 ([2 M + Na]+, 29). HRMS-ESI
(m/z): cald for C19H17N4O [M + H]+ 317.1402, found 317.1416.
Synthesis of Imidate (8). To a solution of iminoester (10 mmol),
prepared according to the method described by Pinner,19 in methanol
and 4-methylbenzonitrile (15/15 mL) was bubbled with dry HCl.
Then, the iminoester was free of its salt, in 50 mL of ether, by a
solution of sodium carbonate. (o-Tolyl or 1-naphthyl)isothiocyanate
(10 mmol) was added dropwise at 0 °C in the iminoester solution.
The mixture was stirred for 2 h, and the ether was evaporated. The
imidate was recrystallized from petroleum ether.
(Z/E)-1-(Methoxy-p-tolyl-methylene)-3-o-tolyl-thiourea (8a).
Yield: 78% (2.32 g). White solid, mp 139−141 °C. IR (KBr, cm−1):
3138, 2943, 1659, 1524, 1436, 1289, 1242, 1208, 1183, 1151, 1099.
MS-(+)ESI, m/z (%): 299 ([M + H]+, 100), 321 ([M + Na]+, 9).
HRMS-ESI (m/z): cald for C17H19N2OS [M + H]+ 299.1218, found
1
299.1208. Z-isomer: H NMR (DMSO-d6, 300 MHz): δ 2.06 (s, 3H,
CH3), 2.35 (s, 3H, CH3), 3.63 (s, 3H, CH3), 7.07−7.24 (m, 4H), 7.27
(d, J = 9 Hz, 2H), 7.57 (d, J = 9 Hz, 2H), 10.82 (br, 1H, NH). 13C
NMR (DMSO-d6, 75 MHz): δ 17.7, 21.5, 55.0, 126.5, 127.1, 127.3,
127.5, 128.7, 129.5, 130.8, 134.1, 137.4, 142.5, 154.9, 189.3. E-isomer:
1H NMR (DMSO-d6, 300 MHz): δ 2.07 (s, 3H, CH3), 2.36 (s, 3H,
CH3), 3.90 (s, 3H, CH3), 7.07−7.24 (m, 4H), 7.32 (d, J = 9 Hz, 2H),
7.79 (d, J = 9 Hz, 2H), 10.67 (br, 1H, NH). 13C NMR (DMSO-d6, 75
MHz): δ 17.9, 21.5, 55.1, 126.5, 127.4, 127.9, 128.1, 128.8, 129.4,
130.8, 134.8, 137.9, 142.0, 156.9, 190.6.
Enantiomer Enrichment and Isolation. 5a. Chiralpak IA (10 ×
250 mm; mobile phase: hexane/ethanol/chloroform 70/10/20; flow: 5
mL/min; UV at 290 nm. Sample preparation: 98 mg in 20 mL of
chloroform and 20 mL of the mobile phase. 100 injections (400 μL).
(Z/E)-1-(Methoxy-p-tolyl-methylene)-3-naphthalen-1-yl-thiourea
(8b). Yield 86% (2.87 g). White solid, mp 134−136 °C. IR (KBr,
cm−1): 3134, 2946, 1675, 1515, 1497, 1280, 1241, 1210, 1158, 1099.
MS-(+)ESI, m/z (%): 335 ([M + H]+, 100). HRMS-ESI (m/z): cald
for C40H36N4NaO2S2 [2M + Na]+ 691.2177, found 691.2177. Z-
isomer: 1H NMR (DMSO-d6, 300 MHz): δ 2.31 (s, 3H, CH3), 3.78 (s,
3H, CH3), 7.26 (d, J = 9 Hz, 2H), 7.35−7.55 (m, 7H), 7.95 (d, J = 9
Hz, 2H), 11.40 (br, 1H, NH). 13C NMR (DMSO-d6, 75 MHz): δ 21.5,
54.8, 123.6, 124.6, 125.7, 126.0, 126.7, 127.0, 127.8, 128.4, 128.7,
Recovery: 40 mg of each enantiomer was obtained (98% ee). αD25
+98 (c 0.24, CHCl3) for the first eluted enantiomer.
=
5b. (S,S)-Ulmo (10 × 250 mm); mobile phase: hexane/ethanol/
chloroform 60/20/20; flow: 5 mL/min; UV at 300 nm. Sample
preparation: 142 mg in 10 mL of chloroform, 10 mL of ethanol and 5
mL of hexane. 36 injections (700 μL). Recovery: 65 mg of each
enantiomer (99% ee). α2D5 = −87 (c 0.26, CHCl3) for the first eluted
enantiomer.
1
129.0, 129.4, 134.0, 134.7, 142.5, 154.9, 190.0. E-isomer: H NMR
(DMSO-d6, 300 MHz): δ 2.40 (s, 3H, CH3), 3.96 (s, 3H, CH3), 7.19
(d, J = 9 Hz, 2H), 7.35−7.55 (m, 7H), 7.87 (d, J = 9 Hz, 2H), 11.12
12582
dx.doi.org/10.1021/jo402149f | J. Org. Chem. 2013, 78, 12577−12584